Todd Girolamo Sells Shares of PROK $PROK
Key Points
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Todd Girolamo, Chief Legal Officer at ProKidney Corp. ($PROK), sold 163,857 shares at an average price of $0. The trade was disclosed in a Form 4 filing with the Securities and Exchange Commission.
ProKidney Corp. Stock Down 8.7%
Shares of ProKidney Corp. ($PROK) traded around $1.67 on Monday, down 8.7% for the day.
ProKidney Corp. Earnings
Analysts Set New Price Targets
About ProKidney Corp.
ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes. It is also involved in the development of cryopreserved versions of rilparencel, including REGEN-006 and REGEN-008 which are both in Phase III clinical trials; REGEN-002, REGEN-003, and REGEN-007 which are in Phase II clinical trials; and REGEN-004 which is Phase I clinical trial. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
Get ProKidney Corp. alerts
New 13F filings, insider trades, and analyst moves on $PROK, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.